Molnupiravir: antiviral oral para el PIF
An oral alternative to GS-441524 with a complementary mechanism of action. Standard dose: 15-20 mg/kg/day. Particularly suited to cats that do not tolerate daily injections.
What is molnupiravir?
Molnupiravir is a broad-spectrum antiviral from the nucleoside analogue family. It was originally developed to treat influenza and later evaluated for COVID-19 in humans. Its efficacy against the FIP virus was discovered by the scientific community and by FIP cat owners around 2021-2022.
Advantages of molnupiravir
No injections needed. It is given in capsules, mixed with food or straight.
Ideal for very anxious cats, or for owners who cannot give injections.
Its price is similar to oral GS, which makes it an affordable alternative.
In standard forms of FIP, the reported cure rates are comparable to GS-441524.
Indicative dosing
Usual dose: 15-20 mg/kg/day, given in one or two doses.
Neurological forms: may need higher doses. Check with your vet.
Duration: 84 days as standard, with possible extensions in complex cases.
When to choose molnupiravir
- Cats that get very stressed by subcutaneous injections
- Owners who struggle to give injections
- Cats that tolerate oral medication well
- As an alternative when GS-441524 is not available
FAQ
Questions about molnupiravir
Clear answers to the most common questions.
The available data suggests cure rates similar to GS-441524 for the standard forms of FIP. There is less published data on neurological forms, though. The choice depends on several clinical factors and on how the cat tolerates it.
It is possible, though generally not advised without a clinical reason for it. Some owners switch when the cat does not tolerate the injections. Any change must be made under veterinary supervision.
The available safety data is encouraging. Molnupiravir was originally evaluated for humans and later adapted for veterinary use. The side effects described in cats are similar to those of GS-441524 and generally mild.
Does your cat have FIP?
Tell us your situation and we'll tell you where to start.